Clinical Trial Update: A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ABSK043, an oral PD-L1 inhibitor, in angiogenic sarcomas; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• ABSK043 (ABSK043)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Sarcoma | Phase 2 | Status: RECRUITING